




The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 162% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 381%, being 127% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	30,353
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,419
Liabilities, Non-Current	0
Other Assets	33
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3.0
Other Revenues	0
Property and Equipment	37
Research and Development	7,408
Selling, General and Administrative Expense	5,242

Output Variable	Value in 1000 USD
Assets	30,423
Liabilities	1,419
Expenses	12,650
Revenues	0
Stockholders Equity	29,004
Net Income	-12,647
Comprehensive Net Income	-12,647
BaseVar	22,248
ECR before Limited Liability	318%
Economic Capital Ratio	381%